Syngene International Expands Biologics Facility with New ADC Bioconjugation Capability

Syngene International Ltd. has confirmed the facts stated in a recent news article published in The Hindu Businessline. The company plans to provide fully integrated, end-to-end services for antibody-drug conjugates (ADCs), from discovery through GMP manufacturing. The new suite will accelerate development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing the company's existing commercial capabilities in payload and linker manufacturing. This investment in bioconjugation capabilities is in the ordinary course of its business and is not deemed to be 'material' as it does not meet any of the Materiality criterion currently as specified under the Industry Standards Note (ISN) on Regulation 30 of the SEBI Listing Regulations.